Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine
- 1 January 1980
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 17 (2), 153-155
- https://doi.org/10.1007/bf00562624
Abstract
Two subjects from each of the three groups of homozygous rapid, heterozygous, and homozygous non-metabolizers (N-oxidation) of sparteine received a single oral dose of debrisoquine. The urinary ratio of debrisoquine/4-hydroxy-debrisoquine, reflecting the individual's capacity to C-hydroxylate debrisoquine, was closely related to his phenotype for sparteine metabolism. This indicates that the two metabolic reactions are controlled by similar if not identical genetic factors.This publication has 5 references indexed in Scilit:
- Influence of the defective metabolism of sparteine on its pharmacokineticsEuropean Journal of Clinical Pharmacology, 1979
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- Hypotensive response to debrisoquine and hydroxylation phenotypeLife Sciences, 1978
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detectionJournal of Chromatography A, 1977